Virax Biolabs Group Ltd (VRAX) income statement
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.33−0.05 (-12.89%)
Close on Nov 20, 2026Market cap $192.24KP/E –Yield –
Virax Biolabs Group Ltd financial ratios
See a number that looks wrong?